Solid Biosciences Inc.
SLDB
$9.54
-$0.39-3.93%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 41.40% | 22.21% | 23.47% | 17.08% | 11.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.63% | 43.08% | 23.83% | 36.60% | 50.04% |
| Operating Income | -37.63% | -43.08% | -23.83% | -36.60% | -50.04% |
| Income Before Tax | -38.80% | -44.44% | -16.88% | -39.88% | -57.47% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -38.80% | -44.44% | -16.88% | -39.88% | -57.47% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -38.80% | -44.44% | -16.88% | -39.88% | -57.47% |
| EBIT | -37.63% | -43.08% | -23.83% | -36.60% | -50.04% |
| EBITDA | -37.97% | -43.56% | -24.18% | -37.11% | -55.56% |
| EPS Basic | 9.06% | 12.73% | 47.30% | 38.60% | 31.53% |
| Normalized Basic EPS | 9.04% | 12.75% | 47.31% | 38.60% | 31.53% |
| EPS Diluted | 9.06% | 12.73% | 47.30% | 38.60% | 31.53% |
| Normalized Diluted EPS | 9.04% | 12.75% | 47.31% | 38.60% | 31.53% |
| Average Basic Shares Outstanding | 52.63% | 65.53% | 121.82% | 127.82% | 129.98% |
| Average Diluted Shares Outstanding | 52.63% | 65.53% | 121.82% | 127.82% | 129.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |